InsidersTradesSigma
Follow the CSL LIMITED stock price and the full directors' dealings record of the company, a listed equity based in Australia. Shares are quoted on the AU market, under the supervision of ASX. Operating in the Health Care sector, CSL LIMITED has recorded 4 reports. Market capitalisation: €66.3bn. The latest transaction was filed on 4 June 2026 (Purchase). Among the most active insiders: Gordon Naylor. All data is accessible without an account.
Analysts rate CSL LIMITED Buy (bullish), based on 16 analysts. Average price target: A$137.19.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
4 of 4 declarations
CSL LIMITED 是一家澳大利亚生物制药公司，专注于开发严重疾病的治疗方法。该公司在澳大利亚证券交易所 XASX 上市。